Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6XR72
UPID:
ZNT10_HUMAN
Alternative names:
Solute carrier family 30 member 10; Zinc transporter 10
Alternative UPACC:
Q6XR72; Q49AL9; Q9NPW0
Background:
The Calcium/manganese antiporter SLC30A10, also known as Solute carrier family 30 member 10 or Zinc transporter 10, plays a crucial role in maintaining intracellular manganese homeostasis. It functions by mediating the efflux of manganese in exchange for extracellular calcium, essential for various neuronal metabolic pathways and preventing manganese-induced cytotoxicity.
Therapeutic significance:
Hypermanganesemia with dystonia 1, a metabolic disorder linked to mutations in the SLC30A10 gene, underscores the protein's critical role in human health. Understanding the function of SLC30A10 could pave the way for innovative treatments for this and potentially other manganese-related disorders.